GENAISSANCE PHARMACEUTICALS –

New Haven, Conn.

Went public 8/2/2000 at $13 per share

Filing Range: 6 mil. shares @ $11 to $13

Shares Outstanding: 21.6 mil. shares

Book Manager: Deutsche Banc Alex. Brown/Bear, Stearns & Co.

Inc./Salomon Smith Barney/ Warburg Dillion Read LLC

Company Counsel: Palmer & Dodge

Manager Counsel: Ropes & Gray

Auditor: Arthur Andersen & Co.

The Company:

Develops drugs specifically for pharmacogenomics. The company is pursing corporate alliances for use of its Clasper technology that enables pharmaceutical partners to identify isogenes, gene variants containing multiple polymorphisms and the corresponding protein isoforms relevant to variable therapeutic response.

Venture Backers:

Canaan Partners

Johnson & Johnson Development Corp.

Chase Capital Partners

Connecticut Innovations Inc.

Alta Partners

Dresdner Kleinwort Benson Private Equity

Financing Rounds:

Number of Round Amt.

Round # Round Date Stage Investors ($ thousands)

1 04/01/1998 1 Early Stage 750.0

2 07/01/1998 2 Later Stage 1900.0

3 05/01/1999 2 Early Stage 10000.0

4 11/23/1999 1 Later Stage 500.0

5 03/08/2000 6 Expansion 47062.1

6 05/22/2000 1 Later Stage 1560.0

Financials:

(Data in $ millions)

Y/E

12/31/99

Total Revenues: $0.6

Net Income: -9.0